Auriga has assumed coverage of United Therapeutics Corp. UTHR at a Buy rating and with a price target of $90.
According to Auriga, “We are assuming coverage of United Therapeutics (UTHR) with a Buy rating and a $90 price target. UTHR reported 1Q11 revenues that were once again below both our and the Street estimates. Management blamed a number of factors including weather, inventory drawdowns, and general lumpiness. Specifically, IV/SQ Remodulin grew 8% Y/Y and was up 1% sequentially. However, Tyvaso was flat sequentially for the third straight quarter and Adcirca declined 12% sequentially. UTHR reiterated timelines for the closely watched FREEDOM-M trial (read out in June) and FREEDOM-C2 (read out in September). UTHR provided initial guidance for 2011, 2012 and 2013 of $750MM, $875MM and $1,000MM (+/- 5%) -- levels modestly below Street expectations (do not include oral Remodulin). Overall, we view the weakness around the quarter as a buying opportunity ahead of the June release of the potentially transformative FREEDOM-M data. We reiterate our Buy and $90 price target.”
UTHR closed yesterday at $67.66.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorInitiationAnalyst RatingsAuriga USABiotechnologyHealth CareUnited Therapeutics Corp.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in